University of Florida Researchers Develop Universal mRNA Cancer Vaccine That Awakens Immune System
核心洞察
University of Florida researchers have developed an experimental mRNA vaccine that boosts tumor-fighting effects of immunotherapy by stimulating general immune responses rather than targeting specific cancer proteins.
The vaccine achieved promising results in mouse models by stimulating PD-L1 (搜索) expression in tumors and enhancing the effectiveness of PD-1 (搜索) inhibitor drugs, with some models showing complete tumor elimination.
This breakthrough suggests a third paradigm in cancer vaccine development that could lead to an off-the-shelf universal cancer vaccine for broad clinical application.
University of Florida researchers have achieved a breakthrough in cancer immunotherapy with the development of an experimental mRNA vaccine that enhances the tumor-fighting effects of existing treatments by awakening the immune system in an entirely new way. Published in Nature Biomedical Engineering, the study demonstrates that a "universal" approach to cancer vaccination could revolutionize treatment for multiple cancer types.
Novel Approach Bypasses Traditional Targeting
The research team, led by senior author Elias Sayour, M.D., Ph.D., a UF Health pediatric oncologist, discovered that their mRNA vaccine achieved promising results not by attacking specific tumor proteins, but by simply revving up the immune system to respond as if fighting a virus. This approach stimulated the expression of PD-L1 (搜索) protein inside tumors, making them more receptive to treatment.
"This paper describes a very unexpected and exciting observation: that even a vaccine not specific to any particular tumor or virus — so long as it is an mRNA vaccine — could lead to tumor-specific effects," said Sayour, principal investigator at the RNA Engineering Laboratory within UF's Preston A. Wells Jr. Center for Brain Tumor Therapy.
Strong Synergy with Checkpoint Inhibitors
In mouse models of melanoma, the research team observed promising results when combining their mRNA formulation with PD-1 (搜索) inhibitors, a common type of monoclonal antibody immunotherapy drug. The combination created a "one-two punch" effect that triggered strong antitumor responses in normally treatment-resistant tumors.
Taking the research further, investigators tested different mRNA formulations as standalone treatments in mouse models of skin, bone, and brain cancers. In some models, the tumors were eliminated entirely, demonstrating the potential power of this approach.
Third Paradigm in Cancer Vaccine Development
Co-author Duane Mitchell, M.D., Ph.D., who directs the UF Clinical and Translational Science Institute, explained the significance of this discovery: "This study suggests a third emerging paradigm. What we found is by using a vaccine designed not to target cancer specifically but rather to stimulate a strong immunologic response, we could elicit a very strong anticancer reaction."
Until now, cancer vaccine development has focused on two main approaches: finding specific targets expressed in many cancer patients, or creating personalized vaccines tailored to individual patient tumors. This new approach offers a potential universal solution.
Building on Previous Success
The current study builds upon Sayour's previous breakthrough in human clinical trials. Last year, his team conducted a first-ever human trial using a personalized mRNA vaccine to attack glioblastoma, an aggressive brain tumor. Among four patients, the vaccine quickly reprogrammed the immune system to reject tumors, demonstrating the rapid effectiveness of mRNA-based cancer immunotherapy.
For more than eight years, Sayour has pioneered anticancer vaccines by combining lipid nanoparticles and mRNA technology. The new "generalized" mRNA vaccine was made using similar technology to COVID-19 vaccines but was engineered to prompt strong immune responses rather than targeting specific viral proteins.
Mechanism of Action
The researchers observed that their mRNA vaccine activated immune responses seemingly unrelated to cancer, which prompted previously inactive T cells to multiply and kill cancer cells when the immune response was strong enough. This mechanism suggests that a sufficiently robust immune activation can overcome the typical immune evasion strategies employed by tumors.
Clinical Translation Pathway
"This finding is a proof of concept that these vaccines potentially could be commercialized as universal cancer vaccines to sensitize the immune system against a patient's individual tumor," said Sayour, who is also a McKnight Brain Institute investigator and co-leader of a program in immuno-oncology and microbiome research.
The implications extend beyond combination therapy. Mitchell noted that the results show potential for a universal cancer vaccine that could activate the immune system and prime it to work with checkpoint inhibitor drugs, or in some cases, work independently to eliminate cancer.
"It could potentially be a universal way of waking up a patient's own immune response to cancer," Mitchell said. "And that would be profound if generalizable to human studies."
The research team is now focused on improving current formulations and advancing to human clinical trials as rapidly as possible, potentially offering a new treatment alternative to surgery, radiation, and chemotherapy for many types of treatment-resistant tumors.